A detailed history of China Universal Asset Management Co., Ltd. transactions in Uni Qure N.V. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 9,922 shares of QURE stock, worth $38,100. This represents 0.01% of its overall portfolio holdings.

Number of Shares
9,922
Previous 9,922 -0.0%
Holding current value
$38,100
Previous $52,000 1.92%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$4.82 - $6.93 $17,660 - $25,391
3,664 Added 58.55%
9,922 $52,000
Q4 2023

May 21, 2024

SELL
$5.63 - $8.27 $20,628 - $30,301
-3,664 Reduced 36.93%
6,258 $42,000
Q4 2023

Jan 23, 2024

BUY
$5.63 - $8.27 $24,293 - $35,685
4,315 Added 222.08%
6,258 $42,000
Q3 2023

May 21, 2024

SELL
$6.71 - $11.83 $114,855 - $202,494
-17,117 Reduced 89.81%
1,943 $13,000
Q3 2023

Oct 30, 2023

SELL
$6.71 - $11.83 $114,855 - $202,494
-17,117 Reduced 89.81%
1,943 $13,000
Q2 2023

May 21, 2024

SELL
$11.12 - $22.2 $144 - $288
-13 Reduced 0.07%
19,060 $218,000
Q2 2023

Jul 27, 2023

SELL
$11.12 - $22.2 $144 - $288
-13 Reduced 0.07%
19,060 $218,000
Q1 2023

May 21, 2024

SELL
$18.7 - $23.07 $2.13 Million - $2.63 Million
-113,907 Reduced 85.66%
19,073 $384,000
Q1 2023

Apr 27, 2023

SELL
$18.7 - $23.07 $2.13 Million - $2.63 Million
-113,907 Reduced 85.66%
19,073 $384,000
Q4 2022

May 21, 2024

BUY
$18.12 - $27.32 $2.23 Million - $3.36 Million
123,058 Added 1240.25%
132,980 $3.01 Million
Q4 2022

Jan 31, 2023

BUY
$18.12 - $27.32 $2.4 Million - $3.62 Million
132,543 Added 30330.21%
132,980 $3.02 Million
Q3 2022

Oct 21, 2022

BUY
$16.98 - $25.54 $7,420 - $11,160
437 New
437 $8,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $179M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.